ATE166656T1 - Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen - Google Patents

Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen

Info

Publication number
ATE166656T1
ATE166656T1 AT92906577T AT92906577T ATE166656T1 AT E166656 T1 ATE166656 T1 AT E166656T1 AT 92906577 T AT92906577 T AT 92906577T AT 92906577 T AT92906577 T AT 92906577T AT E166656 T1 ATE166656 T1 AT E166656T1
Authority
AT
Austria
Prior art keywords
human
galanin
galamine
code
cdna clones
Prior art date
Application number
AT92906577T
Other languages
English (en)
Inventor
Helen Frances Evans
John Shine
Original Assignee
Garvan Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garvan Inst Med Res filed Critical Garvan Inst Med Res
Application granted granted Critical
Publication of ATE166656T1 publication Critical patent/ATE166656T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT92906577T 1991-03-06 1992-03-06 Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen ATE166656T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPK495391 1991-03-06

Publications (1)

Publication Number Publication Date
ATE166656T1 true ATE166656T1 (de) 1998-06-15

Family

ID=3775264

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92906577T ATE166656T1 (de) 1991-03-06 1992-03-06 Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen

Country Status (6)

Country Link
EP (1) EP0587571B1 (de)
JP (1) JP3135262B2 (de)
AT (1) ATE166656T1 (de)
CA (1) CA2105572A1 (de)
DE (1) DE69225706T2 (de)
WO (1) WO1992015681A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE819167T1 (de) 1996-01-24 1998-04-09 Synaptic Pharma Corp Dns codierend für galanin galr2 rezeptoren und deren verwendung
US5972624A (en) * 1996-01-24 1999-10-26 Synaptic Pharmaceutical Corporation Method of identifying ligands which bind recombinant galanin receptor (GALR2)
DK1342410T3 (da) * 1996-07-24 2010-05-31 Neurotargets Ltd Anvendelse af en galaninagonist til fremstilling af et medikament til forbedring af hukommelse og andre kognitive funktioner
US6329197B2 (en) 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
CA2326694A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Galanin receptor galr3 and nucleotides encoding same
CN1189495C (zh) 1999-04-09 2005-02-16 迪纳尔生物技术公司 用于制备单分散聚合物颗粒的方法
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2006047302A1 (en) 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
EP2187941A2 (de) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Verwendung eines galanin-peptids als therapeutisches mittel

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1350792A (en) * 1991-01-16 1992-08-27 General Hospital Corporation, The Human galanin
AU1462692A (en) * 1991-02-25 1992-09-15 Board Of Regents Of The University Of Washington, The Methods for detecting galanin antagonists

Also Published As

Publication number Publication date
EP0587571A1 (de) 1994-03-23
EP0587571B1 (de) 1998-05-27
JP3135262B2 (ja) 2001-02-13
JPH06508984A (ja) 1994-10-13
EP0587571A4 (de) 1995-03-15
WO1992015681A1 (en) 1992-09-17
DE69225706D1 (de) 1998-07-02
DE69225706T2 (de) 1998-11-26
CA2105572A1 (en) 1992-09-07

Similar Documents

Publication Publication Date Title
ATE229072T1 (de) Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendung
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
TW327194B (en) Novel amyloid precursor proteins and methods of using same
ATE166656T1 (de) Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen
NZ271756A (en) Human macrophage inflammatory proteins and coding sequences, their production and use
NO179253C (no) Rekombinant DNA-sekvens som koder for humant proapolipoprotein A-I, ekspresjonsvektorer, cellekulturer samt fremgangsmåte for fremstilling av proteinet
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
DE69433790D1 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
EP1541686A4 (de) Antikörperkonstruktion unter verwendung einer mrl/lpr-maus
BR9710665A (pt) Compostos que promovem o desenvolvimento do tecido
DK413488D0 (da) Dna-klon med en basissekvens for human vaevsfaktorinhibitor (tfi) og dna-sekvens, der koder for tfi
LU93259I2 (fr) LETIFEND (Protein Q)
NZ508505A (en) Treatment of wounds using an Egr-1 transcription factor polypeptide
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
UA39165C2 (uk) Молекула днк, що кодує ліпазу людини, що стимулюється солями жовчних кислот, клонована молекула кднк
NO930428D0 (no) Proteinstrukturen til plantetoksingelonin
DE69534470T2 (de) Lgmd- gen kodierend für eine calcium-abhängige protease
DK1261712T3 (da) Proteiner benævnt FXTRC og nucleinsyrer kodende for samme
HUP9900789A2 (hu) Lefelé irányuló szabályozásra rezisztens C3 konvertáz
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
PT704527E (pt) Sequencias de adn que codificam precursores de insulina biossinteticos e processo para a preparacao de insulina
EP1270588A4 (de) NEUESKOLLAGEN-äHNLICHES PROTEIN CLAC, DESSEN VORLäUFER UND DAFüR KODIERENDE GENE
AR025482A1 (es) Secuencia de adn que codifica una proteina capaz de ligarse a traf; vector que comprende dicha secuencia; celulas huespedes transformadas con dicho vector;proteinas iren codificadas por dicha secuencia; metodo para producir dicha proteina; anticuerpos especificos para dichas proteinas; metodo para m
DE69536127D1 (de) Transformierender wachstumsfaktor alpha hii
PT811068E (pt) Variantes da adnase i humana

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties